Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585364 · ClinicalTrials.gov registry record
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 79
- Enrollment target
NCT00585364: Completed study, sponsored by University of Pittsburgh.
NCT00585364 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00585364 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs. In patients with cystic fibrosis (CF), this fungus is not known to cause damage to the lungs, but some patients respond with an allergic reaction that may cause wheeze, cough, or difficulty breathing. Approximately 230 patients will be enrolled with an additional 60 people who do not have CF and who do not have a history of asthma to serve as a comparison group.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-12 |
What the finished NCT00585364 record still lists
NCT00585364 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 79 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00585364 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00585364 about?
NCT00585364 is a clinical study titled "Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA". The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs. In patients with cystic fibrosis (CF), this fungus is not known to cause damage to the lungs, but some patients respond...
What is the current status of trial NCT00585364?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2005-03. Estimated completion is 2010-12.
Who is sponsoring clinical trial NCT00585364?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia